LAVAL, QC, Oct. 25 /PRNewswire-FirstCall/ - LAB International Inc. (“LAB”), an integrated drug development company with subsidiaries focused on developing therapies for the inhalation market and on providing contract research services, today announced that Dr. Halvor Jaeger, Chief Executive Officer of the Company, will present at the PIPEs Conference 2005 on Wednesday, October 26, 2005, at 11.00 am and 3.00pm and Thursday, October 27, 2005, at 8.00 am at the Waldorf-Astoria Hotel in New York.
A live webcast of the Wednesday, October 26, 2005, 11.00 am presentation will be available on LAB’s website in the Investor Relations section at www.labinc.ca . A replay will be available for a period of 30 days.
The PIPEs Conference 2005 features investors, investment bankers, attorneys, company executives, and industry analysts active in the small cap equity market. The conference includes CLE-accredited workshops, roundtables, and presentations from leading industry professionals.
About LAB International
LAB International (LAB Pharma and LAB Research) is an integrated drug development company. LAB Pharma is focused on the growing multi-billion dollar inhalation market. Its lead product, for the treatment of breakthrough cancer pain, is a fast-acting Fentanyl formulation delivered using the Company’s TAIFUN(R) dry powder inhaler platform. Its pipeline also includes therapeutics for asthma, COPD, and growth hormone deficiencies. LAB Research is a profitable and growing contract research services division supporting its clients base from state-of-the-art facilities in Canada, the US, Denmark and Hungary.
LAB’s common shares trade on The Toronto Stock Exchange (“TSX”) under the symbol “LAB”, on the Frankfurt Regulated Unofficial Market under the symbol “LD9.F” and on XETRA under the symbol “LD9.DE” with 56.0 million shares outstanding.
This news release contains certain forward-looking statements that reflect the current views and/or expectations of LAB International Inc. with respect to its performance, business and future events. Such statements are subject to a number of risks, uncertainties and assumptions. Actual results and events may vary significantly.
LAB INTERNATIONAL INC.
CONTACT: visit LAB’s website at www.labinc.ca, or contact: Luc Mainville,Chief Operating Officer, (450) 973-2240 ext. 1206, Fax: (450) 973-2259,mainvillel@labinc.ca; Frederic Dumais, Director, Communication and InvestorRelations, (450) 973-2240 ext. 1207, Fax: (450) 973-2259,dumaisf@labinc.ca; Kim Sutton Golodetz, Investor Relations (U.S.A), (212)838-3777, Fax: (212) 838-4568, kgolodetz@lhai.com
